Head of the Institute of Virology, Faculty of Veterinary Medicine, at the Justus-Liebig-Universität Giessen, Germany; Member of the Leopoldina (German Academy of Sciences); Member of two study groups of ICTV (International Committee on Taxonomy of Viruses); Member of Editorial Board for Veterinary Microbiology
Dr Vincent Thomas obtained is PharmD degree in 1999 (Paris XI University). He defended his PhD in the field of microbial ecology (interactions between Legionella pneumophila, biofilms and protozoa) in 2004 in the same University, and then spent 2-years as a post doc at CHUV hospital (Lausanne, Switzerland) to investigate interactions between Free-Living Amoebae and various microorganisms. In 2006, he took a position as a senior researcher at STERIS Corp. to develop a microbiology lab located in the premises of the French Nuclear Agency (CEA, Fontenay-aux-Roses, France) and directed at disinfectant mechanisms of activity against emerging infectious agents including prion, various viruses, protozoa and drug-resistant bacteria. He obtained his HDR (Accreditation to supervise research in microbiology) in 2012, and then left to join the French startup Enterome in 2013. He was specifically in charge of the development and validation of an industrial platform dedicated to DNA extraction, biobanking, metagenomics sequencing and bioinformatic analysis for the analysis of gut microbiota in close association with INRA-Metagenopolis. Dr Vincent Thomas joined the Technological Research Institute BIOASTER in 2015 as head of the Biological Collections and Microbiology Unit. He is now head of the Microbiota Program in the same Institute, being specifically in charge of positioning the Institute’s strategy and vision in the field of microbiota research.
Infectious diseases physician at the Victorian Infectious Diseases Service, Royal Melbourne Hospital. Co-head Translational and Clinical Research and Co-head Indigenous Health at Doherty Institute for Infection and Immunity, University of Melbourne. Deputy Chair of the Australasian Society for Infectious Diseases Clinical Research Network.
Emeritus Professor of Pharmacology (Catholic University of Louvain, Brussels, Belgium) and Emeritus Professor of Human Biochemistry and Biochemical Pathology (University of Mons, Mons, Belgium).
The Elizabeth and John Shapiro Professor of Pathology and Professor of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine. Deputy Editor for The Journal of Immunology, Consulting Editor for the Journal of Clinical Investigation. Director of the Microbiology and Immunology Course for medical students at Vanderbilt University School of Medicine.
After performing her PhD thesis at the National Institutes of Health (NIH, Bethesda, USA) from 1991 to 1994 and a postdoctoral fellowship in New York from 1994 to 1997, Carine Van Lint joined the Faculty of Sciences of the "Université Libre de Bruxelles" as the head of the Laboratory of Molecular Virology. As a biochemist, Carine Van Lint has developed for the last 25 years a specific interest for pathogenic retroviruses. Her laboratory is mainly studying the role played by epigenetic modifications (such as histone acetylation, histone methylation and DNA methylation) and by non-epigenetic regulatory elements in transcriptional latency and reactivation of HIV-1 (Human Immunodeficiency Virus type 1 - the ethiologic agent of the acquired immunodeficiency syndrome (AIDS)), BLV (Bovine Leukemia Virus - the etiologic agent of a chronic lymphoproliferative disease termed enzootic bovine leucosis) and HTLV-1 (Human T-cell leukemia virus 1 - the etiologic agent of an aggressive lymphoproliferative disease (Adult T-cell Leukemia/Lymphoma) and a neurological degenerative syndrome (tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM)).
Professor of Microbiology at the Faculty of Medicine. Head of the clinical microbiology department and head of a research INSERM team in the field of staphylococcal pathogenesis. Head of the French Reference Center for Staphylococci.
Research fellow at National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in Bethesda, Maryland, USA. Specialist in cytokine biology and STAT signaling.
Principal Investigator of Chemical Biology Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences; Council Member of Asian Pacific Society for Neurochemistry. Recipient of CAS Pioneer Hundred Talents Program, Migraine Research Foundation Award,Chinese Pharmaceutical Association (CPA)-Sanofi Award for Young Scientists in Bio-medicine, ISN -CAEN Award, APSN Young Investigator Award, ISN-ESN Young Investigator Award.
Katrine Whiteson uses metagenomics, metabolomics, microbiology and ecological statistics to answer questions about how microbes and viruses affect human health. She studied Biochemistry at UC Berkeley (BA, 2000) and University of Chicago (PhD, 2007). During her PhD, Dr. Whiteson focused on the active site chemistry and DNA binding specificity of a site-specific recombinase from the class of proteins that enable the spread of antibiotic resistance genes. In 2008, she began a new job at the University of Geneva Hospitals with Dr. Jacques Schrenzel and Dr. Patrice Francois. This was an exciting era, just at the start of the Human Microbiome Project, for asking basic unanswered questions about the microbes and viruses inhabiting various niches of the human body. Dr. Whiteson focused on the oral microbial communities of healthy Europeans, and malnourished kids in Niger who develop a devastating facial gangrene known as noma. In 2011 she moved to Forest Rohwer’s lab at San Diego State, where she undertook breath and sputum metabolite analysis to better understand the activity of CF patient microbial communities from Dr. Doug Conrad’s Adult CF clinic at UCSD. Combining information about the genetic potential of a microbial community through DNA sequencing with the activity of the community by metabolite profiling is a powerful approach that Dr. Whiteson hopes to employ in future projects as she begins her own lab at University of California Irvine in Fall 2014.
Microbiologist at the University of Auckland, New Zealand. Recipient of the inaugural 3Rs award from the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) in 2005 and the New Zealand National Animal Ethics Advisory Committee (NAEAC) 3Rs award in 2011. Awarded the New Zealand Association of Scientists Science Communicator Prize in 2012 and NZ Prime Minister's Science Media Communication Prize and Royal Society of New Zealand Callaghan Medal in 2013.
Adam's research interests span the fields of computational analysis of complex datasets, such as microarray data, next generation sequencing (NGS) and genomics data, and the design and implementation of biological databases.
Since 2001 Adam has been the lead bioinformatics scientist in the Wellcome Trust funded bacterial microarray group (BµG@S) in the Institute of Infection and Immunity. There, he was responsible for designing multiple pan genome pathogen microarrays.
Currently, he plays a central role in multiple collaborative projects and activities across several research centres and institutes within St George's, University of London and St George’s Healthcare NHS Trust, as well as externally.
Specifically, Adam is developing computational pipelines for the implementation of NGS analysis within the context of clinical microbiology, and has applied these to various pathogens. such as Mycobacterium tuberculosis and Pseudomonas aeruginosa. He is also involved in various research projects investigating the genomics of Neisseria gonorrhoea and Klebsiella pneumoniae in clinical samples.
He is also the lead architect and software developer on several database systems currently implemented within St George’s NHS Trust Infection Control and within research projects in the university.